Tuesday, 7/26 –
The Cellular, Tissue, and Gene Therapies Advisory Committee
will meet by teleconference for updates on research programs in the Laboratory of Molecular Oncology and the Laboratory of Biological Chemistry, Division of Biotechnology Review and Research I and IV, Office of Biotechnology Products (OBP), CDER, FDA. The meeting will take place beginning at 1 p.m. on the FDA’s White Oak Campus, Silver Spring, Md. For those unable to attend in person, there will be a live webcast
of the meeting.
On the Web:
In Case You Missed It:
Thursday, 7/21 –
FDA Voice Blog: Practical Applications of FDA Regulations for the Indian Food Industry
. Globalization of the food supply chain and advances in food processing technologies have led American consumers to develop a taste for a variety of foods and cuisines from different countries. Increasingly, U.S. grocery stores sell foods from Asia, Latin America, and many other parts of the world. Indian exporters have recognized this marketing opportunity, and FDA data show an increase in U.S. imports from India over the past 10 years. A wealth of ready-to-eat Indian specialties can be found in cans and bottles on U.S. store shelves including Indian curries (gravies), canned sweets, pickled cucumbers, and Indian pickles (chopped fruits and vegetables marinated in brine).
Tuesday, 7/19 –
News Release: Federal court orders Minnesota sprout and noodle company to cease operations due to unsanitary conditions
. On July 15, 2016, the U.S. District Court for the District of Minnesota entered a consent decree of permanent injunction between the United States and Kwong Tung Foods, Inc., doing business as Canton Foods; its president and owner, Vieta “Victor” C. Wang; and its vice-president, Juney H. Wang, for significant and ongoing violations of the Federal Food, Drug, and Cosmetic Act and its implementing regulations. The business, located in Minneapolis, Minn., sells rice and wheat noodles, and mung bean and soy bean sprouts.
Tuesday, 7/19 –
FDA Voice Blog: Addressing Global Challenges through Transatlantic Cooperation
. On a recent trip to Brussels, our FDA delegation met with many of our European Union regulatory counterparts and stakeholders to discuss ways to strengthen our shared commitment to product safety and public health. Reflecting the broad scope of our transatlantic dialogue, we engaged on an array of issues, including supply chain safety, quality metrics, risk-based surveillance, data integrity, mutual reliance, and food safety systems.
Monday, 7/18 –
FDA Voice Blog: The Rise in Orphan Drug Designations: Meeting the Growing Demand
. Developing drugs for rare diseases, once considered a rare phenomenon itself, has fast become a mainstay for many companies’ drug development pipelines. This is exciting news for the 30 million Americans with rare diseases and their families.